netFormulary

Dulaglutide Trulicity^®

Formulary

0.75mg, 1.5mg, 3mg and 4.5mg prefilled syringes
- Approved for use in patients who require once-weekly GLP-1 receptor agonist therapy.
- This has replaced once-weekly exenatide. Existing patients can continue to receive exenatide until reviewed by a specialist

Exenatide

Formulary

5 microgram and 10 microgram per dose are prefilled injection pens containing a 250microgram/ml solution for subcutaneous injection.
- Only approved for use in accordance with NICE guidance Treatment must be initiated by a consultant diabetologist and use is limited to overweight patients with type 2 diabetes in line with NICE guidelines.
2.5mg/0.85ml prolonged-release suspension for injection
- temporarily approved due to supply issues with semaglutide and dulaglutide (please refer to linked advice below)

Lixisenatide

Formulary

Semaglutide

Formulary

0.25mg/0.19mL, 0.5mg/0.37mL and 1mg/0.7mL solution for injection pre-filled pen (Ozempic®)
- Approved for the treatment of type 2 diabetes in patients who require an intensification in treatment
3mg, 7mg & 14mg tablets (Rybelsus®) - BLACK TRIANGLE
- Approved as an option for patients with type 2 diabetes mellitus who require intensification of treatment, if use of a glucagon-like peptide 1 receptor agonist (GLP1RA) is clinically appropriate, in line with licensing and relevant guidance, and if an oral option is preferred.
0.25mg/0.37ml, 0.5mg/0.37ml, 1mg/0.75ml, 1.7mg/0.75ml & 2.4mg/0.75ml solution for injection pre-filled pens (Wegovy®)
- Approved for managing overweight and obesity in line with NICE guidance within a specialist weight management service (including but not limited to tiers 3 and 4)
- Also available via NHSE pilot sites involving primary care
- Note: As of 29^th April 2024 there is an ICB weight management strategy in development which is seeking to review the arrangements and capacity of current service provision across the ICS

Tirzepatide Mounjaro^®

Formulary

Liraglutide

Formulary

Victoza^®
- Approved for the treatment of type 2 diabetes mellitus in accordance with NICE guidance

Saxenda^®
- Approved as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults in line with NICE and providing:
  - it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service; and